Author(s)

Junyi Li ¹, Jing Liu ², Jike Li ², Ru Han ², Juan Li ²

Affiliation(s)

¹ Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
² Xi'an Hospital of Traditional Chinese Medicine, Xi'an, Shaanxi, 710021, China

Corresponding Author

Jing Liu

ABSTRACT

Heart failure is the end stage of cardiovascular disease. It has the characteristics of high medical cost, high mortality and poor quality of life of patients. Its treatment is a difficult and hot topic in the field of cardiovascular research. In order to treat heart failure, it is necessary to understand the specific mechanism of its occurrence. With the continuous discussion and research on the mechanism of heart failure, signal pathways related to heart failure are also constantly being discovered. Interleukin-6 / signal transducer and activator of transcription 3 (IL-6 / STAT3) is one of the more novel pathways. In the early days, IL-6 / STAT3 signaling pathway was more used in the field of cancer. In recent years, more and more studies have shown that IL-6 / STAT3 signaling pathway can also affect the occurrence and development of heart failure by affecting myocardial inflammation, myocardial fibrosis, myocardial energy metabolism and so on. This article focuses on the relationship between IL-6 / STAT3 signaling pathway and heart failure.

KEYWORDS

Heart Failure, IL-6; STAT 3, IL-6 / STAT 3 Signaling Pathway

CITE THIS PAPER

Junyi Li, Jing Liu, Jike Li, Ru Han, Juan Li, Research Progress on IL-6 / STAT 3 Signaling Pathway in Heart Failure. MEDS Basic Medicine (2024) Vol. 2: 145-150. DOI: http://dx.doi.org/10.23977/medbm.2024.020119.

REFERENCES

[1] The Writing Committee of the Report on Cardiovascular Health And Diseases In China. (2023). Report on Cardiovascular Health and Diseases in China 2022: an Updated Summary. Biomedical and environmental sciences : BES. 2023 Aug 20; 36(8):669-701.
[2] Wang H, Chai K, Du M, et al. Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis. Circ Heart Fail, 2021, 14(10): e008406.
[3] Mamas M A, Sperrin M, Watson MC, et al. Do patients have worse outcomes in heart failure than in cancer?A primary carebased cohort study with 10-year follow-up in Scotland. Eur J Heart Fail, 2017, 19(9): 1095-1104. 10; 392(10159):1789-1858.
[4] Cai Qiu, Zhou Yang. Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database-Heart Failure Center Registry. Eur J Heart Fail. 2022, 24(11): 2048-2062.
[5] Cook C, Cole G, Asaria P, Jabbour R, Francis D P. The annual global economic burden of heart failure. Int J Cardiol. 2014, 171(3): 368–376.
[6] Kemp C D, Conte J V. The pathophysiology of heart failure. Cardiovasc Pathol. 2012, 21(5): 365-371.
[7] Wang Zhang. Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction. Heart Fail Rev. 2023, 28(1): 169-178.
[8] Sarah A Dick, Slava Epelman. Chronic Heart Failure and Inflammation: What Do We Really Know? Circ Res. 2016, 119(1): 159-176.
[9] Pal Aukrust, Arne Yndestad, Jan K Damås, Lars Gullestad. Therapeutic potential of anticytokine therapy in congestive heart failure. Am J Cardiovasc Drugs. 2004, 4(3): 169-177.
[10] Godo S, Suda A, Takahashi J, Yasuda S, Shimokawa H.Coronary microvascular dysfunction. Arterioscler Thromb Vasc Biol. 2021, 41(5): 1625–1637.
[11] Deng J. Research progress on the molecular mechanism of coronary microvascular endothelial cell dysfunction. Int J Cardiol Heart Vasc. 2021 Apr, 10(34): 100777.
[12] Cheng W, Li X, Liu D, Cui C, Wang X.Endothelial-to-mesenchymal transition: role in cardiac fibrosis. J Cardiovasc Pharmacol Ther. 2021, 26(1): 3–11.
[13] Sun X, Nkennor B, Mastikhina O, Soon K, Nunes S S. Endothelium-mediated contributions to fibrosis. Semin Cell Dev Biol. 2020, 101: 78–86.
[14] Van Empel V P. Myocyte apoptosis in heart failure. Cardiovasc Res. 2005, 67(1): 21-29.
[15] C Du, M Fang, Y Li. A mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 2000, 102(1): 33-42.
[16] C Adrain, S J Martin. The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. Trends Biochem Sci. 2001 Jun, 26(6): 390-397.
[17] Lopaschuk G. D., Karwi Q.G., Tian R., Wende A.R., Abel E .D. Cardiac Energy Metabolism in Heart Failure. Circ.Res. 2021, 128: 1487–1513.
[18] Dei Cas A., Khan S.S., Butler J., Mentz R.J., Bonow R.O., Avogaro A., Fonarow G.C.Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC. 2015, 3: 136–145.
[19] Z Zhong, Z Wen. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994, 264(5155): 95-98.
[20] Diane L Hevehan, William M Miller, Eleftherios T Papoutsakis. Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation. Blood. 2002 Mar 1, 99(5): 1627-1637.
[21] W Zhang, X Qu, B Chen. Critical roles of STAT3 in β-adrenergic functions in the heart. Circulation. 2016, 133(1): 48-61.
[22] Wang M, Han X, Yu T. OTUD1 promotes pathological cardiac remodeling and heart failure by targeting STAT3 in cardiomyocytes. Theranostics. 2023, 13(7): 2263-2280.
[23] Ye S, Luo W, Khan Z A. Celastrol Attenuates Angiotensin II-Induced Cardiac Remodeling by Targeting STAT3. Circ Res. 2020, 126(8): 1007-1023.
[24] Daichi Enomoto, Masanori Obana, Akimitsu Miyawaki. Cardiac-specific ablation of the STAT3 gene in the subacute phase of myocardial infarction exacerbated cardiac remodelling. Am J Physiol Heart Circ Physiol. 2015, 309(3): 471-480.
[25] Tanaka T, Narazaki M, Masuda K. Regulation of IL-6 in Immunity and Diseases. Adv Exp Med Biol. 2016, 941: 79-88.
[26] Sukhvir Kaur, Yogita Bansal, Raj Kumar. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorg Med Chem. 2020, 28(5): 115327.
[27] V Eskandari, A A Amirzargar, M J Mahmoudi. Gene expression and levels of IL-6 and TNFα in PBMCs correlate with severity and functional class in patients with chronic heart failure. Ir J Med Sci .2018, 187(2): 359-368.
[28] Ishibashi T, Kimura H, Shikama Y.Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 1989, 74(4): 1241-1244.
[29] Konrad Hoeft, Gideon J L Schaefer, Hyojin Kim. Platelet-instructed SPP1+ macrophages drive myofibroblast activation in fibrosis in a CXCL4-dependent manner. Cell Rep. 2023, 42(2): 112-131.
[30] Yasuhiro Izumiya, Ichiro Shiojima, Kaori Sato. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 2006, 47(5): 887-893.
[31] Cohen T, Nahari D, Cerem L W, Neufeld G, Levi B Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996, 271(2): 736-741
[32] Jacoby Kalinowski. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Natl Acad Sci USA. 2003, 100(22): 29-34.
[33] Rose-John S. IL -6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012, 8(9): 37-47.
[34] Huo S, Shi W, Ma H. Alleviation of Inflammation and Oxidative Stress in Pressure Overload-Induced Cardiac Remodeling and Heart Failure via IL-6/STAT3 Inhibition by Raloxifene. Oxid Med Cell Longev. 2021, 21: 6699054.
[35] Zhang Z, Tang J, Song J. Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling. Free Radic Biol Med. 2022, 181: 130-142.
[36] Li F, Li S S, Chen H. miR-320 accelerates chronic heart failure with cardiac fibrosis through activation of the IL6/STAT3 axis. Aging (Albany NY). 2021, 13(18): 22516-22527.
[37] Hikmet Nural-Guvener, Liudmila Zakharova, Lorraine Feehery, Snjezana Sljukic, Mohamed Gaballa. Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure. Int J Mol Sci. 2015, 16(5): 11482–11499.
[38] Jiang T, Peng D, Shi W. IL-6/STAT3 Signaling Promotes Cardiac Dysfunction by Upregulating FUNDC1-Dependent Mitochondria-Associated Endoplasmic Reticulum Membranes Formation in Sepsis Mice. Front Cardiovasc Med. 2022, 18(8): 790612.
[39] Sun J Y, Du L J, Shi X R. An IL-6/STAT3/MR/FGF21 axis mediates heart-liver cross-talk after myocardial infarction. Sci Adv. 2023, 9(14): 4110.

Sponsors, Associates, and Links

---

• MEDS Clinical Medicine
  
  
• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine